Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
3 clusters · 8 sources · 33 days · First seen · Last updated
Pharmaceutical pricing trends in Serbia
Overview
In Serbia, pharmaceutical prices increased by 7.8 percent in September compared to the previous year, despite government efforts to mitigate costs. Former President Aleksandar Vučić had previously announced a relief package of approximately 104.8 million euros (12.3 billion dinars) intended to expand the list of state-subsidized prescription drugs and lower patient co-payments.
Prime Minister Đuro Macut announced that 18 new prescription drugs, including oral anticoagulants, would be covered by the state starting in mid-August. However, economists suggest that pharmaceutical companies may be increasing prices on non-subsidized products to offset lost profits.
The rising costs are placing significant financial strain on vulnerable populations. In 2025, the poverty risk for those aged 65 and older was 25.8 percent, while the poverty risk among pensioners stood at 23.4 percent. For many elderly citizens, managing fixed incomes against the rising costs of food, utilities, and essential healthcare remains a critical challenge.
Entities
Đuro Macut · Aleksandar Vučić · Batiste · Serbia · Garnier
Timeline
-
[BUSINESS] 4 sourcesSerbia faces rising medicine costs despite government promises
Medicine prices in Serbia rose 7.8 percent in September, contradicting government promises to lower costs through subsidies and expanded state-funded prescription lists.
-
[HEALTH] 2 sourcesPharmaceutical prices rise despite government subsidy efforts
Despite Serbian government initiatives to subsidize medicines and reduce co-payments, pharmaceutical prices rose by 7.8 percent in September. Experts suggest using generic alternatives to save costs.
-
[BUSINESS] 2 sourcesRetail pricing and consumer psychology in Serbia
Retail analysis in Serbia highlights how psychological pricing like 'free shipping' and significant price gaps between drugstores dm and Lilly impact consumer spending and savings.
Sources
blikkruzs.blikk.hu · bonitet.com · infokg.rs · koreni.rs · sandzaklive.rs · srpskainfo.com · szabadmagyarszo.com · telegraf.rs
This summary has been updated 1 time: see revision history